Other studies have reported the synthesis of radiolabeled technetium- and thenium-LHRH conjugated to detect and target BC cells overexpressing LHRH receptors [106], and an LHRH receptor-targeted and tumor microenvironment-responsive nanoparticle system (LHRH-DCMs) to deliver selectively chemotherapeutic drugs to triple-negative BC cells has been published [107]. The gene discussed is GNRH1; the disease is breast cancer.